Showing 101 - 120 results of 271 for search 'King of Thailand', query time: 0.05s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116
  17. 117

    Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection by Ruamviboonsuk V, Kongwattananon W, Chuaypen N

    Published 2025-02-01
    “…Varis Ruamviboonsuk,1,2 Wijak Kongwattananon,1,3 Natthaya Chuaypen4 1Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 2Medical Science Program, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 4Metabolic Diseases in Gut and Urinary System Research Unit (MeDGURU), Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCorrespondence: Wijak Kongwattananon, Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand, Tel +662 256 4000, Email wijak.k@chula.ac.thPurpose: Intravitreal brolucizumab, approved for neovascular age-related macular degeneration (nAMD), may trigger immune responses leading to intraocular inflammation (IOI) by increasing pro-inflammatory cytokines. …”
    Get full text
    Article
  18. 118
  19. 119
  20. 120